The new 2023 FIGO staging system for endometrial cancer: what is different from the previous 2009 FIGO staging system?
Journal of Gynecologic Oncology · 2024 · 35 (5)
DOI: 10.3802/jgo.2024.35.e59 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2024. Verfasst von Kyung Hee Han und 4 weiteren Autor:innen. Beteiligte Einrichtung: Gynecologic Cancer Center, Department of Obstetrics and Gynecology, CHA University Ilsan Medical Center, Goyang, Korea. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Neoplasm Staging. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Seoul National University Hospital Research Fund, Seoul National University College of Medicine Research Foundation, SNUH.
Abstract (Originalsprache)
OBJECTIVE: The International Federation of Gynecology and Obstetrics committee modified the endometrial cancer (EC) staging system based on the histopathological feature and molecular profile. The aim is to evaluate the clinical implications of the new 2023 system compared with the previous 2009 system. METHODS: We retrospectively identified 161 patients with EC who underwent primary surgical treatment between 2014 and 2018 at Seoul National University Hospital. The droplet-digital polymerase chain reaction for POLE mutations and immunohistochemistry for MLH1, PMS2, MS2, MSH6, and p53 were performed using tissues from formalin-fixed, paraffin-embedded blocks. All patients were categorized according to the 2009 and 2023 staging systems. RESULTS: The median follow-up period was 62.9 months (range, 0.3-110.9), and the median age was 57.2 years old (range, 28.0-85.9). The 5-year progression-free survival (PFS) for the 2023 system with molecular classification was 80.3% for stage I, 75.2% for stage II, 61.2% for stage III, and 22.2% for stage IV (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gynecologic Cancer Center, Department of Obstetrics and Gynecology, CHA University Ilsan Medical Center, Goyang, Korea.
- Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea. pnhkhr@snu.ac.kr.
- Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
- Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.
- Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea.
ORCID-Profile: Kyung Hee Han, NohHyun Park, Maria Lee, Cheol Lee, Hyojin Kim
Förderung
- Seoul National University Hospital Research Fund
- Seoul National University College of Medicine Research Foundation
- SNUH
- SNUCM
Zitieren
APA
Han, K. H., Park, N., Lee, M., Lee, C., & Kim, H. (2024). The new 2023 FIGO staging system for endometrial cancer: what is different from the previous 2009 FIGO staging system?. Journal of Gynecologic Oncology, 35(5). https://doi.org/10.3802/jgo.2024.35.e59
Vancouver
Han KH, Park N, Lee M, Lee C, Kim H. The new 2023 FIGO staging system for endometrial cancer: what is different from the previous 2009 FIGO staging system?. Journal of Gynecologic Oncology. 2024;35(5). doi:10.3802/jgo.2024.35.e59
BibTeX
@article{Han2024,
author = {Han, Kyung Hee and Park, NohHyun and Lee, Maria and Lee, Cheol and Kim, Hyojin},
title = {The new 2023 FIGO staging system for endometrial cancer: what is different from the previous 2009 FIGO staging system?},
journal = {Journal of Gynecologic Oncology},
year = {2024},
volume = {35},
number = {5},
doi = {10.3802/jgo.2024.35.e59}
}
EUVIMED